Voyager Therapeutics (NASDAQ:VYGR) Stock Price Passes Above 50-Day Moving Average - What's Next?

Key Points

• Voyager Therapeutics shares briefly moved above their 50-day moving average of $3.36, reaching $3.40 before closing at $3.32; trading volume was 716,940 shares.
• Analyst views remain mixed, but the stock carries a consensus “Moderate Buy” rating and a $16.50 price target. Ratings include one Strong Buy, two Buys, and one Sell.
• Voyager reported a quarterly loss of $0.40 per share, better than the expected $0.48 loss, while revenue of $3.17 million fell short of estimates. Institutional investors own approximately 48.03% of the company.

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report)'s share price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $3.36 and traded as high as $3.40. Voyager Therapeutics shares last traded at $3.32, with a volume of 716,940 shares traded.

Wall Street Analysts Forecast Growth

VYGR has been the subject of several analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Voyager Therapeutics in a report on Monday, July 13th. Wall Street Zen lowered Voyager Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. Finally, HC Wainwright reissued a "buy" rating on shares of Voyager Therapeutics in a research report on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Voyager Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $16.50.

Voyager Therapeutics Stock Down 2.6%

The company has a market cap of $204.57 million, a PE ratio of -1.84 and a beta of 1.31. The stock has a 50-day simple moving average of $3.36 and a 200 day simple moving average of $3.69.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.08. The business had revenue of $3.17 million during the quarter, compared to analysts' expectations of $4.52 million. Voyager Therapeutics had a negative return on equity of 57.92% and a negative net margin of 312.63%. As a group, research analysts anticipate that Voyager Therapeutics, Inc. will post -1.63 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of VYGR. BlackRock Inc. acquired a new stake in Voyager Therapeutics in the 2nd quarter valued at approximately $18,102,000. EcoR1 Capital LLC raised its position in Voyager Therapeutics by 497.2% in the fourth quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company's stock valued at $15,731,000 after purchasing an additional 3,332,544 shares during the period. Opaleye Management Inc. acquired a new position in Voyager Therapeutics during the fourth quarter worth $4,704,000. AQR Capital Management LLC lifted its stake in Voyager Therapeutics by 179.3% during the first quarter. AQR Capital Management LLC now owns 495,260 shares of the company's stock worth $1,674,000 after purchasing an additional 317,927 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Voyager Therapeutics by 95.0% during the first quarter. Renaissance Technologies LLC now owns 578,024 shares of the company's stock worth $2,231,000 after buying an additional 281,574 shares during the period. Hedge funds and other institutional investors own 48.03% of the company's stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company's core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm's pipeline includes several AAV-based candidates in preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source